– FRANCE, Paris – STENTYS (Paris:STNT), a medical technology company commercializing the XPOSITION S self-apposing coronary stent, today announces that the STENTYS Board of Directors has decided to co-opt Professor Christian Spaulding and Mrs. Sophie Baratte as independent Board members.
Professor Christian Spaulding is Professor of Cardiology at Paris Descartes University and Head of the Interventional Cardiology department at the Georges-Pompidou European Hospital, Paris. A member of the Cardiac Arrest Research Center at the PARCC Institute (Paris Cardiovascular Research Center), he has published more than 240 research articles in world-renown peer-reviewed scientific journals, notably on the issue of coronary stents and percutaneous coronary intervention techniques.
Mrs. Sophie Baratte is Chief Executive Officer of medical technology company Cellnovo. She has spent the majority of her career in senior positions at major healthcare companies such as Johnson & Johnson, Sorin Group, CIT and Lifecell. She thus has extensive experience in sales and marketing, notably in bringing innovative technologies to market.
Subject to these appointments being approved by the Annual General Meeting of May 11, 2017, Stentys’ 5-member Board of Directors will thus have 4 independent directors.
Michel Darnaud, Chairman of the Board, comments: “I am delighted to welcome to our Board of Directors two experts who will be able to support us in the implementation of our growth strategy: Professor Christian Spaulding, interventional cardiologist, international expert, who heads the Interventional Cardiology department at the Georges-Pompidou European Hospital, and Sophie Baratte, who has substantial experience in the sales and marketing of innovative medical devices. Thanks to their respective know-how, we have solid assets to enable us to continue taking STENTYS forward and upward to become a benchmark player in its field”.
About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS’ Self-Apposing drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America.
For more information : http://www.stentys.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
